Saturday 17 October 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
9.95
0.32
−3.12%
Follow ZVRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.02 | 6.54 | 4.55 | 15.09 |
P/S ratio |
6.31 | 4.65 | 4.45 | 6.23 | |
P/FCF ratio |
0.00 | 0.00 | 43.60 | 25.65 | |
P/Operating CF |
113.00 | 89.85 | 88.63 | 49.81 | |
P/B ratio |
4.00 | 3.20 | 2.65 | 3.90 | |
Price to Tangible BV |
4.37 | 3.45 | 2.79 | 4.09 | |
EV/Sales |
5.11 | 3.80 | 3.63 | 5.34 | |
EV/EBITDA |
0.00 | 0.00 | 8.43 | 9.01 | |
EV/Operating CF |
(18.47) | (252.94) | 34.73 | 21.75 | |
EV/FCF |
(18.20) | (203.63) | 35.51 | 21.96 | |
Quick Ratio |
8.29 | 5.46 | 4.74 | 5.02 | |
Current Ratio |
8.62 | 5.68 | 4.89 | 5.17 | |
Net Debt/EBITDA |
(41.58) | (14.64) | (3.87) | (13.39) | |
Debt/Assets |
22.70% | 21.75% | 0.00% | 0.00% | |
Debt/Equity |
0.46 | 0.40 | 0.00 | 0.00 | |
Asset Turnover |
0.37 | 0.46 | 0.54 | 0.49 | |
Operating CF/Net income |
(8.66) | 0.41 | 0.17 | 2.03 | |
Capex/Depreciation |
(0.04) | 0.22 | (171.65) | (20.52) | |
Interest Coverage |
2.02 | 4.78 | 30.48 | — | |
Research and Development Expense of Revenue |
13.17% | 7.68% | 12.13% | 11.31% | |
Selling, General and Administrative Expense of Revenue |
64.98% | 59.65% | 57.38% | 41.75% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.03 | |
Share Based Compensation of Revenue |
10.63% | 12.55% | 8.57% | 7.49% | |
Graham Net Nets |
0.17 | 0.19 | 0.29 | 0.20 | |
Graham Number |
5.17 | 9.28 | 12.75 | 8.87 | |
Earnings Yield |
5.26% | 15.29% | 22.00% | 6.62% | |
Free Cash Flow Yield |
(4.46%) | (0.40%) | 2.29% | 3.90% | |
Revenue per Share |
0.47 | 0.62 | 0.62 | 0.67 | |
Operating CF per Share |
0.08 | 0.10 | 0.11 | 0.29 | |
Capex per Share |
0.00 | 0.00 | 0.75 | 0.08 | |
Free Cash Flow per Share |
0.08 | 0.10 | 0.86 | 0.37 | |
Cash per Share |
3.57 | 3.45 | 3.43 | 3.75 | |
Shareholders Equity per Share |
2.38 | 2.80 | 3.52 | 3.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.38 | 2.80 | 3.52 | 3.68 | |
Free Cash Flow |
4.74 | 5.41 | 50.08 | 21.77 | |
Working Capital |
199.00 | 183.73 | 182.94 | 202.67 | |
Capital Expenditures |
0.04 | (0.11) | 43.94 | 4.74 | |
Net Current Asset Value |
88.16 | 92.93 | 157.19 | 166.24 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 8.82 | |
Capex to Sales |
0.00 | 0.00 | (1.21) | (0.12) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 10.30 | |
| Other line items | |||||
Average Receivables |
12.32 | 16.88 | 17.36 | 20.38 | |
Average Payables |
17.77 | 18.53 | 14.75 | 14.90 | |
Average Inventory |
— | 1.86 | 2.43 | 1.78 | |
Average Assets |
230.83 | 231.43 | 225.64 | 279.49 | |
Average Common Equity |
101.47 | 97.16 | 123.41 | 167.44 |
Columns are period end dates